Akouos receives IND clearance for AK-OTOF gene therapy for OTOF-mediated hearing loss
Sep. 14, 2022
Akouos Inc. has received IND clearance from the FDA to initiate a first-in-human phase I/II pediatric trial of AK-OTOF, a gene therapy intended for the treatment of patients with otoferlin gene (OTOF)-mediated hearing loss.